(AOF) – Geneuro, a biopharmaceutical company, has appointed Anke Post as Chief Medical Officer, following the retirement of David Leppert, Medical Director since April 2020. Anke Post will bring her extensive academic and medical experience to the field of neuroscience, psychiatry and neurology, as well as extensive experience in the pharmaceutical industry. She has worked for 25 years developing drugs for psychiatric and neurodegenerative diseases, including ALS.
She brings her drug development experience to all phases of development, including leading teams on international projects, contract research organizations, and managing interactions with regulatory authorities.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.